

STEP THERAPY CRITERIA

BRAND NAME
(generic)

VELPHORO
(sucroferric oxyhydroxide)

Status: CVS Caremark® Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Velphoro is indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30-day supply of calcium acetate (e.g., PhosLo) within the past 120 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed to control serum phosphorus levels in a patient with chronic kidney disease who is receiving dialysis
AND
 - The patient has experienced an inadequate treatment response to calcium acetate (e.g., PhosLo)**OR**
 - The patient has experienced an intolerance to calcium acetate (e.g., PhosLo)**OR**
 - The patient has a contraindication that would prohibit a trial of calcium acetate (e.g., PhosLo)**OR**
 - It has been determined that calcium acetate (e.g., PhosLo) is not appropriate for the patient (e.g., due to hypercalcemia, arterial calcification, adynamic bone disease, or low parathyroid hormone [PTH] levels)

Duration of Approval (DOA):

- 2048-D: DOA: 12 months

REFERENCES

1. Velphoro [package insert]. Waltham, MA: Fresenius Medical Care North America; February 2020.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed October 5, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 10/5/2023).
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl.* 2017;7:1–59.

Velphoro ST, Post PA Policy 2048-D UDR 11-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.